Could stem cells help scarred lungs? new trial begins
Disease control
Not yet recruiting
This early-phase trial tests a stem cell product called REGEND007 for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. Twelve adults aged 40–80 will receive a single IV infusion to see if it is safe and tolerable. The st…
Phase: EARLY_PHASE1 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated May 26, 2026 07:59 UTC